Abstract
Fremanezumab, a fully humanized monoclonal antibody (IgG2Δa) that selectively targets calcitonin gene-related peptide (CGRP), has demonstrated efficacy for migraine prevention in patients with episodic or chronic migraine (EM or CM) with documented inadequate response to 2–4 classes of prior preventive migraine medications in the phase 3b FOCUS study. This subgroup analysis evaluated the efficacy of fremanezumab in patients with baseline medication overuse (simple analgesics ≥15 days/month of triptans, ergots, barbiturate- or opioid-containing analgesics ≥10 days/month).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have